Opinion|Videos|October 2, 2024
Key Takeaways and Clinical Practice Pearls in the Treatment of Patients with Breast Cancer Receiving ADCs
Panelists discuss how addressing unmet needs in patient selection, resistance mechanisms, and long-term outcomes can enhance the efficacy of antibody-drug conjugates in breast cancer treatment.
Advertisement
Episodes in this series
Video content above is prompted by the following:
Can you share some of the biggest unmet need(s) or treatment gaps that still exist for patients with breast cancer who are receiving antibody-drug conjugates and some practice pearls you wish to share with your community colleagues?
Advertisement
Related to this article
The 510(k) clearance covers an MRI-derived AI risk score for stage I to IIIA disease; the high-risk category carried an HR of 2.81 for recurrence.
The top 5 OncLive TV videos of the week cover insights in multiple myeloma, HR+ breast cancer, CAR T-cell therapy, CLL, and oral SERDs.
Nunnery and Bond discuss how patients and advocates can navigate second opinions, mental health support, and the long-term effects of cancer treatment.
Invikafusp alfa now holds fast track status across TMB-H solid tumors that progressed after prior therapy, including checkpoint inhibition.
Matthew P. Goetz, MD, explores menopausal status, recurrence risk, and adjuvant CDK4/6 inhibitor selection in HR-positive breast cancer.
Matthew P. Goetz, MD, explores first-line treatment selection, emerging targeted therapies, and unmet sequencing needs in metastatic breast cancer.
Readers share their opinions on some of the most talked-about breast cancer abstracts they’re looking forward to seeing at ESMO 2026.
The top 5 OncLive TV videos of the week.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Dostarlimab for dMMR/MSI-H Locally Advanced Rectal Cancer
2
VOLGA, DASL-HiCaP Data Highlight Key Genitourinary Cancer Presentations Arriving at ESMO 2026
3
FDA Clears TumorSight Risk, an MRI-Derived AI Recurrence Tool for HR+, HER2– Breast Cancer
4
Japan Approves On-Body Injector for Subcutaneous Isatuximab in Multiple Myeloma
5